

22<sup>nd</sup> September, 2022

- |   |  |
|---|--|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                                |  |

**Sub: Closure of US FDA product-specific Pre-Approval Inspection**

Dear Sir/Madam,

Further to the intimation dated 4<sup>th</sup> July, 2022, this is to inform you that following the product specific Pre-Approval Inspection (PAI) by the United States Food and Drug Administration (USFDA) at the Indore plant from 27<sup>th</sup> June, 2022 to 1<sup>st</sup> July, 2022, the Company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection.

Kindly take the above information on record.

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

Prepared by: Mandar Kurghode